Keywords: amgen/abigenix, panitumumab, enters, ph, iii, amgen, fellow

Amgen/Abigenix' panitumumab enters Ph III

Article | 16 May 2005

Print This

Amgen and fellow US firm, Nasdaq-listed Abgenix, have initiated a Phase III clinical study to evaluate the potential benefits of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in